Timio M, Gentili S, Schiaroli M, Ronconi M
G Ital Cardiol. 1979;9(12):1371-7.
A new oral vasodilator, prazosin, was evaluated in twenty patients with refractory congestive heart in a double blind non cross-over trial. Patients were divided into two groups. The first (group A) was treated by prazosin (40-50 microgram/Kg/pro die) for 20 days, the second was given placebo for the same period. Ventricular performance was assessed by measurement of the systolic time intervals, the peak time of the first derivative of the apexcardiogram (delta ACG), pressure-rate product and clinical evaluation. After ten days of prazosin left ventricular ejection time (LVET) increased (P < 0.01), pre-ejection period (PEP) and relation PEP/LVET were reduced (respectively: P < 0.05 and P < 0.01). Similarly the peak of delta ACG and pressure-rate product decreased significantly (respectively: P < 0.05 and P < 0.01). Symptomatology improved in NYHA functional class (3.7 to 2.4, P < 0.001). After twenty days of prazosin there was no further significant improvement in myocardial performance. No significant changes of clinical course and of the same parameters were observed in patients of group B. It is concluded that prazosin is effective in improving cardiac performance in refractory heart failure for its balanced dilator action on the arteriolar and venous vessels.
一种新型口服血管扩张剂哌唑嗪，在一项双盲非交叉试验中，对20例难治性充血性心力衰竭患者进行了评估。患者被分为两组。第一组（A组）接受哌唑嗪治疗（40 - 50微克/千克/日），为期20天，第二组在同一时期给予安慰剂。通过测量收缩期时间间期、心尖搏动图一阶导数的峰值时间（δACG）、压力 - 心率乘积以及临床评估来评估心室功能。使用哌唑嗪10天后，左心室射血时间（LVET）增加（P < 0.01），射血前期（PEP）以及PEP/LVET比值降低（分别为：P < 0.05和P < 0.01）。同样，δACG峰值和压力 - 心率乘积也显著降低（分别为：P < 0.05和P < 0.01）。纽约心脏病协会（NYHA）心功能分级的症状有所改善（从3.7降至2.4，P < 0.001）。使用哌唑嗪20天后，心肌功能没有进一步的显著改善。B组患者的临床病程和相同参数没有观察到显著变化。得出结论，哌唑嗪因其对小动脉和静脉血管的平衡扩张作用，在改善难治性心力衰竭的心脏功能方面是有效的。
